Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of May 20, 2026, ANVS trades at $1.59 with a market cap of $71.03M and a P/E ratio of -1.41. ANVS moved -5.85% today. Year to date, ANVS is -46.85%; over the trailing twelve months it is -8.49%. Its 52-week range spans $1.11 to $10.54. Analyst consensus is buy with an average price target of $12.50. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Annovis Bio Launches Public Offering of Stock and Warrants to Fund Phase 3 Study: Annovis Bio has launched a proposed underwritten public offering of common stock alongside warrants, with Canaccord Genuity as sole bookrunner. Net proceeds will fund the Phase 3 clinical development of oral drug candidate buntanetap for Alzheimer’s disease and support working capital and corporate purposes.
| Metric | Value |
|---|---|
| Price | $1.59 |
| Market Cap | $71.03M |
| P/E Ratio | -1.41 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.54 |
| 52-Week Low | $1.11 |
| Volume | 727.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.85M |
| Gross Margin | 0.00% |
2 analysts cover ANVS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.50.